Supporting pharmacists in improving the care delivered for people with cancer The Pharmaceutical Journal has launched a cancer ‘hub page’ and educational resources on blood cancer as part of continued partnership with BeiGene.… Promotional content
Medicines derived from UK blood plasma distributed to NHS hospitals for ‘first time in a generation’ More than 250,000 litres of plasma from UK donors have been sent to human protein product manufacturer Octapharma to produce NHS medicines for the first time since a 1998 ban.…
Standard-dose DOACs not necessarily better than reduced dose, study results suggest Researchers found that “non-inferiority” of a reduced dose of direct oral anticoagulants could not be determined when compared with a standard dose, with “reliably low rates” of recurrent venous thromboembolism.…
NICE recommends once-weekly injection for severe blood clotting disorder Efanesoctocog alfa, a once-weekly treatment for patients with severe haemophilia A, removes the need for frequent dosing, owing to its effective bleeding control.…
NICE approves gene-editing sickle cell therapy for NHS in England Exagamglogene autotemcel, also known as exa-cel, is now recommended for NHS use, reversing previous draft guidance.…
New class of anticoagulant found to ‘overwhelmingly’ reduce bleeding events in patients with atrial fibrillation Experts say the results of this “exciting” two-year study of abelacimab “add to the growing evidence that inhibition of factor XI may preferentially impact thrombosis over haemostasis”.…
Nearly 92% of atrial fibrillation patients in England anticoagulated, says NHS adviser The UK Health Security Agency has achieved the figure five years ahead of its original 2029 target year by offering anticoagulation to nine in ten patients with atrial fibrillation.…
Statin prescribing in England at record high, show NICE data Figures show that atorvastatin prescribing increased from 4.2 million people in 2022/2023 to 5.0 million people in 2023/2024.…
Manufacturer withdraws treatment for sickle cell disease following concern over deaths Pfizer's withdrawal is based on data that suggest “an imbalance in vast-occlusive crises and fatal events which require further assessment”.…
Lipid-lowering therapies for the secondary prevention of cardiovascular disease in primary care An overview of updated guidance relating to the secondary prevention of cardiovascular disease can be applied in practice, considering the availability of newer medications.…
